MedPath

Post marketing study of sofosbuvir and ribavirin for hepatitis C virus genotype 2 infectio

Not Applicable
Conditions
Hepatitis C virus infection
Registration Number
JPRN-UMIN000023269
Lead Sponsor
Wakayama Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1)pregnant woman 2)decompensated cirrhosis 3)severe renal function(<eGFR30)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sustained virological response at 12 weeks after the end of treatment
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath